Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy

被引：113

作者：

de Botton, S ^{[1
]}

Sanz, MA ^{[1
]}

Chevret, S ^{[1
]}

Dombret, H ^{[1
]}

Martin, G ^{[1
]}

Thomas, X ^{[1
]}

Mediavilla, JD ^{[1
]}

Recher, C ^{[1
]}

Ades, L ^{[1
]}

Quesnel, B ^{[1
]}

Brault, P ^{[1
]}

Fey, M ^{[1
]}

Wandt, H ^{[1
]}

Machover, D ^{[1
]}

Guerci, A ^{[1
]}

Maloisel, F ^{[1
]}

Stoppa, AM ^{[1
]}

Rayon, C ^{[1
]}

Ribera, JM ^{[1
]}

Chomienne, C ^{[1
]}

Degos, L ^{[1
]}

Fenaux, P ^{[1
]}

机构：

[1] Univ Paris 13, Hop Avicenne, Serv Hematol Clin, F-93009 Bobigny, France

来源：

LEUKEMIA | 2006年 / 20卷 / 01期

关键词：

acute promyelocytic leukemia; extramedullary relapse; all-trans retinoic acid;

D O I：

10.1038/sj.leu.2404006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We analyzed the incidence, presenting features, risk factors of extramedullary ( EM) relapse occurring in acute promyelocytic leukemia (APL) treated with all-trans retinoic acid ( ATRA) and chemotherapy by using a competing-risk method. In total, 740/806 (92%) patients included in three multicenter trials (APL91, APL93 trials and PETHEMA 96) achieved CR, of whom 169 (23%) relapsed, including 10 EM relapses. Nine relapses involved the central nervous system (CNS) and one the skin, of which two were isolated EM relapse. In patients with EM disease, median WBC count was 26 950/mm(3) (7700-162000). The 3-year cumulative incidence of EM disease at first relapse was 5.0%. Univariate analysis identified age < 45 years (P = 0.05), bcr3 PML-RAR alpha isoform (P = 0.0003) and high WBC counts (>= 10000/ mm 3) (P < 0.0001) as risk factors for EM relapse. In multivariate analysis, only high WBC count remained significant (P = 0.001). Patients with EM relapse had a poorer outcome since median survival from EM relapse was 6.7 months as compared to 26.3 months for isolated BM relapse (P = 0.04). In conclusion, EM relapse in APL occurs more frequently in patients with increased WBC counts (X10000/mm(3)) and carries a poor prognosis. Whether CNS prophylaxis should be systematically performed in patients with WBC X10000/mm(3) at diagnosis remains to be established.

引用

页码：35 / 41

页数：7

共 25 条

[11] Extramedullary relapse after all-trans retinoic acid treatment in acute promyelocytic leukemia -: the occurrence of retinoic acid syndrome is a risk factor [J].

Ko, BS ;

Tang, JL ;

Chen, YC ;

Yao, M ;

Wang, CH ;

Shen, MC ;

Tien, HF .

LEUKEMIA, 1999, 13 (09) :1406-1408

[12]

Liso V, 1998, CANCER, V83, P1522, DOI 10.1002/(SICI)1097-0142(19981015)83:8<1522::AID-CNCR6>3.0.CO

[13]

2-4

[14]

Mandelli F, 1997, BLOOD, V90, P1014

[15]

MARRA R, 1989, HAEMATOLOGIA, V22, P195

[16] Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate [J].

Ohno, R ;

Asou, N ;

Ohnishi, K .

LEUKEMIA, 2003, 17 (08) :1454-1463

[17] ANALYSIS OF FAILURE TIMES IN PRESENCE OF COMPETING RISKS [J].

PRENTICE, RL ;

KALBFLEISCH, JD ;

PETERSON, AV ;

FLOURNOY, N ;

FAREWELL, VT ;

BRESLOW, NE .

BIOMETRICS, 1978, 34 (04) :541-554

[18]

Sanz MA, 1999, BLOOD, V94, P3015

[19] Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy:: a multicenter study by the PETHEMA group [J].

Sanz, MA ;

Martín, G ;

González, M ;

León, A ;

Rayón, C ;

Rivas, C ;

Colomer, D ;

Amutio, E ;

Capote, FJ ;

Milone, GA ;

de la Serna, J ;

Román, J ;

Barragán, E ;

Bergua, J ;

Escoda, L ;

Parody, R ;

Negri, S ;

Calasanz, MJ ;

Bolufer, P .

BLOOD, 2004, 103 (04) :1237-1243

[20]

Sanz MA, 2000, HAEMATOLOGICA, V85, P758

← 1 2 3 →